| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Tech Observer is a global Contract Research Organization (CRO) founded in 2005, with its headquarters in Paramus, New Jersey, and additional offices in New Delhi, Mumbai, and Singapore. The company specializes in clinical development support for the pharmaceutical, biotechnology, and medical device industries, extending its reach through local partners across the Asia-Pacific region. The company offers a comprehensive range of services that encompass the entire clinical research process. These include managing clinical trials, clinical data management, biostatistics and SAS programming, medical writing, post-marketing clinical studies, and staffing services. Tech Observer is ISO 9001:2008 and ISO 14155:2011 certified, demonstrating its commitment to quality and regulatory compliance. With a workforce of around 400 professionals, the company serves over 50 clients in more than 30 countries, focusing on various therapeutic areas such as oncology, cardiology, and infectious diseases. Tech Observer also emphasizes innovation with solutions like its AI-driven clinical trial risk tool, MyRBQM, and promotes diversity and professional growth within its team.
Scale your team with high-quality, vetted professionals. 🚀 MSH is a global technology and talent solutions provider that empowers people and the places they work to thrive. The companys leading-edge services and support provide organizations with the business intelligence and high-quality, vetted candidates they need to succeed at a speed and scale others cannot in 35+ markets across three continents. By engaging MSHs human-centered and collaborative platform, hiring leaders and talent professionals are empowered to find the highest quality candidates, while putting the candidate experience front and center. Founded in 2011 and headquartered in Fort Lauderdale, Fla., MSH is certified as a Minority Business Enterprise by the National Minority Supplier Development Council.
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees around the world, the company contributes to sustainable society by providing solutions to the worlds challenges through its three business sectors of Material, Homes, and Health Care.